TY - JOUR T1 -奈多克米尔钠治疗运动性哮喘:一项荟荟性分析JF -欧洲呼吸杂志JO - Eur Respir J SP - 30 LP - 37 VL - 16 IS - 1 AU - Spooner, C AU - Rowe, BH AU - Saunders, LD Y1 - 2000/07/01 UR - //www.qdcxjkg.com/content/16/1/30.abstract N2 -运动性哮喘(或支气管收缩)折磨着全球数百万人。虽然它通常是自限性的，但它会妨碍表现和降低活动水平，因此它是诊断和治疗的重要条件。本综述的目的是评估单剂量奈多克米尔钠对运动性哮喘的预防作用。检索了Cochrane Airways Group试验登记册、Cochrane对照试验登记册、当前内容、相关文章参考列表、综述文章和教科书，以寻找在6岁人群中比较单剂量奈多克米尔与安慰剂预防运动诱发哮喘的随机试验。作者和药物制造商被联系进行额外的试验。试验质量评估和数据提取由两名审稿人独立进行。尽可能联系作者。共纳入20项试验。所有研究均被评为方法质量良好。奈多克米尔可抑制各年龄组的支气管收缩。 The pooled weighted mean difference for the maximum percentage fall in forced expiratory volume in one second was 15.6%, (95% confidence interval (95% CI): 13.2-18.1) and for the peak expiratory flow was 15.0% (95% CI: 8.3-21.6). These differences are both statistically and clinically significant. After nedocromil the time to recover normal lung function was <10 min compared to >30 min with placebo. Nedocromil had a greater effect on people with a fall in lung function of >30% from baseline. There were no significant adverse effects reported with this short-term use. In conclusion, Nedocromil taken before exercise appears to reduce the severity and duration of exercise-induced bronchoconstriction. This effect appears to be more pronounced as severity increases. ER -